<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-04844R3</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0004778</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Immunology</subject><subject>Infectious Diseases</subject><subject>Immunology/Genetics of the Immune System</subject></subj-group></article-categories><title-group><article-title>Cytokine Gene Polymorphisms across Tuberculosis Clinical Spectrum in Pakistani Patients</article-title><alt-title alt-title-type="running-head">Gene Polymorphisms in TB</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ansari</surname><given-names>Ambreen</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Talat</surname><given-names>Najeeha</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jamil</surname><given-names>Bushra</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hasan</surname><given-names>Zahra</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Razzaki</surname><given-names>Tashmeem</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dawood</surname><given-names>Ghaffar</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hussain</surname><given-names>Rabia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Pathology &#x00026; Microbiology Department, The Aga Khan University, Karachi, Pakistan</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Pathology, Microbiology &#x00026; Medicine Department, The Aga Khan University, Karachi, Pakistan</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Sindh Institute of Urology and Transplantation, Karachi, Pakistan</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Masoomeen General Hospital, Karachi, Pakistan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Ratner</surname><given-names>Adam J.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Columbia University, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>rabia.hussain@aku.edu</email></corresp><fn fn-type="con"><p>Performed the experiments: AA NT. Analyzed the data: AA NT. Wrote the paper: AA. Extra pulmonary patients recruitment and diagnosis: BJ. Optimization of PCR conditions and training: ZH. Design of experiment and critical reading of the manuscript: TR. Recruitment of Pulmonary patients and diagnosis: GD.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>10</day><month>3</month><year>2009</year></pub-date><volume>4</volume><issue>3</issue><elocation-id>e4778</elocation-id><history><date date-type="received"><day>27</day><month>5</month><year>2008</year></date><date date-type="accepted"><day>4</day><month>2</month><year>2009</year></date></history><copyright-statement>Ansari et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>Pakistan ranks 7<sup>th</sup> globally in terms of tuberculosis (TB) disease burden (incidence 181/100000 pop./yr; prevalence of 329/pop./yr). Reports from different populations show variable associations of TB susceptibility and severity with cytokine gene polymorphisms. Tuberculosis clinical severity is multi-factorial and cytokines play a pivotal role in the modulation of disease severity. We have recently reported that the ratio of two key cytokines (IFN&#x003b3; and IL10) show significant correlation with the severity spectrum of tuberculosis. The objective of the current study was to analyze the frequency of cytokine gene polymorphisms linked to high and low responder phenotypes (IFN&#x003b3; &#x0002b;874 <italic>T</italic><sup>hi</sup>&#x02192;<italic>A</italic><sup>lo</sup> and IL10 &#x02212;1082 <italic>G</italic><sup>lo</sup>&#x02192;<italic>A</italic><sup>hi</sup>) in tuberculosis patients.</p></sec><sec><title>Methods and Findings</title><p>Study groups were stratified according to disease site as well as disease severity: Pulmonary N&#x0200a;&#x0003d;&#x0200a;111 (Minimal, PMN&#x0200a;&#x0003d;&#x0200a;19; Moderate, PMD&#x0200a;&#x0003d;&#x0200a;63; Advance, PAD&#x0200a;&#x0003d;&#x0200a;29); Extra-pulmonary N&#x0200a;&#x0003d;&#x0200a;67 (Disseminated DTB&#x0200a;&#x0003d;&#x0200a;20, Localized LTB&#x0200a;&#x0003d;&#x0200a;47) and compared with healthy controls (TBNA&#x0200a;&#x0003d;&#x0200a;188). Genotype analyses were carried out using amplification refractory mutation system-PCR (ARMS-PCR) and stimulated whole blood (WB) culture assay was used for assessing cytokine profiles. Our results suggest that the IFN&#x003b3; &#x0002b;874 <italic>TT</italic> genotype and <italic>T</italic> allele was overrepresented in PMN (p&#x0200a;&#x0003d;&#x0200a;0.01) and PMD (p&#x0200a;&#x0003d;&#x0200a;0.02). IFN&#x003b3; &#x0002b;874 <italic>TT</italic> in combination with IL10 <italic>GG</italic><sup>lo</sup> genotypes showed the highest association (&#x003c7;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;6.66, OR&#x0200a;&#x0003d;&#x0200a;6.06, 95&#x00025; CI&#x0200a;&#x0003d;&#x0200a;1.31&#x02013;28.07, <italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.01). IFN&#x003b3; <italic>AA</italic><sup>lo</sup> on the other hand in combination with IL10 <italic>GG</italic><sup>lo</sup> increased the risk of PAD (OR&#x0200a;&#x0003d;&#x0200a;5.26; p&#x0200a;&#x0003d;&#x0200a;0.005) and DTB (OR&#x0200a;&#x0003d;&#x0200a;3.59; p&#x0200a;&#x0003d;&#x0200a;0.045).</p></sec><sec><title>Conclusion</title><p>These findings are consistent with the role of IL10 in reducing collateral tissue damage and the protective role of IFN&#x003b3; in limiting disease in the lung.</p></sec></abstract><counts><page-count count="7"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Pakistan ranks 7<sup>th</sup> globally in terms of tuberculosis disease burden with an incidence of 181/100000 pop./yr and a prevalence of 329/ pop. /yr. Several reports from different countries have shown that household contacts of active pulmonary tuberculosis are at much higher risk of latent infection that range from 30&#x02013;80&#x00025; depending on the intensity of tuberculosis disease transmission <xref ref-type="bibr" rid="pone.0004778-Akhtar1">&#x0005b;1&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0004778-Lemos1">&#x0005b;4&#x0005d;</xref>. Only ten percent of those latently infected individuals develop TB disease during their lifetime <xref ref-type="bibr" rid="pone.0004778-Comstock1">&#x0005b;5&#x0005d;</xref>. Identification of these high-risk individuals in recently exposed/ infected individuals is of great importance to TB Control Programs for reducing the disease burden in the community. Association of pathological severity with increased circulating levels of different pro-inflammatory and or down-regulatory cytokines in tuberculosis is fairly well established <xref ref-type="bibr" rid="pone.0004778-Ferraz1">&#x0005b;6&#x0005d;</xref>. An increasing number of studies have shown that single nucleotide polymorphisms (SNPs) located in the promoter or coding regions of cytokine genes result in differential cytokine secretion due to altered transcriptional activation. In humans, families with SNPs in IFN&#x003b3; receptor 1 <xref ref-type="bibr" rid="pone.0004778-Dorman1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004778-Altare1">&#x0005b;8&#x0005d;</xref> genes have shown Mendelian susceptibility to tuberculosis. Single nucleotide polymorphisms (SNPs) located in the first intron of the IFN&#x003b3; gene (at position &#x0002b;874) have shown variable associations with tuberculosis disease susceptibility and severity <xref ref-type="bibr" rid="pone.0004778-Pacheco1">&#x0005b;9&#x0005d;</xref>. IFN&#x003b3; (&#x0002b;874<italic>T</italic><sup>hi</sup>&#x02192;<italic>A</italic><sup>lo</sup>) polymorphism is located within a putative NF-kb binding site and shows preferential binding to the <italic>T</italic> allele and correlates with high IFN&#x003b3; producer phenotype <xref ref-type="bibr" rid="pone.0004778-Pravica1">&#x0005b;10&#x0005d;</xref>. Similarly polymorphisms in IL10 <xref ref-type="bibr" rid="pone.0004778-Rees1">&#x0005b;11&#x0005d;</xref> linked to high and low producer phenotypes have shown conflicting associations with tuberculosis disease susceptibility and disease severity in different patient populations <xref ref-type="bibr" rid="pone.0004778-Ates1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004778-Oh1">&#x0005b;13&#x0005d;</xref>. This is not surprising as, although IFN&#x003b3; may be a key cytokine in activation of macrophages for mycobacterial stasis and killing <xref ref-type="bibr" rid="pone.0004778-Flynn1">&#x0005b;14&#x0005d;</xref>, disease severity outcomes in tuberculosis depend on the balance among several different cytokines <italic>in situ</italic>, depending on the disease site. IL10 is particularly important in reducing collateral tissue damage, particularly in the lung by dampening macrophage activation and by indirectly antagonizing IFN&#x003b3; function <xref ref-type="bibr" rid="pone.0004778-OGarra1">&#x0005b;15&#x0005d;</xref>. We have recently reported that the ratio of these two key cytokines (IFN&#x003b3;/IL10) shows significant correlation with clinical severity in extra-pulmonary tuberculosis <xref ref-type="bibr" rid="pone.0004778-Jamil1">&#x0005b;16&#x0005d;</xref>,with higher IFN&#x003b3;/IL10 ratio relating to less severe disease. We have now extended these studies to analyze the frequency of high and low responder cytokine phenotypes (IFN&#x003b3; &#x0002b;874 <italic>T</italic><sup>hi</sup>&#x02192;<italic>A</italic><sup>lo</sup> and IL10 &#x02212;1082 <italic>G</italic><sup>lo</sup>&#x02192;<italic>A</italic><sup>hi</sup>) to analyze the relationship of these SNPs with clinical severity of tuberculosis. Our results show that SNPs in IFN&#x003b3; are significantly related to site of TB disease (Pulmonary <italic>vs.</italic> Extrapulmonary) while combinations of SNPs in IFN&#x003b3; and IL10 genes are important determinants of TB disease severity. Our results therefore substantiate our aim of the study.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Demographic characteristics of the study groups</title><p>There were no significant differences in age in TBNA and TBA groups (<xref ref-type="table" rid="pone-0004778-t001">Table 1</xref>). The ratio of females was significantly higher (<italic>p</italic>&#x0003c;0.05) in TBA compared to TBNA. However, no significant association of genotype with age or sex was observed in both TBA and TBNA (&#x0003e;0.05) using multiple logistic regression analysis (data not shown).</p><table-wrap id="pone-0004778-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004778.t001</object-id><label>Table 1</label><caption><title>Demographic characteristics of TB Patients and Controls.</title></caption><graphic id="pone-0004778-t001-1" xlink:href="pone.0004778.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004778-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Group Studied</td><td align="left" rowspan="1" colspan="1">N</td><td colspan="2" align="left" rowspan="1">Gender</td><td colspan="2" align="left" rowspan="1">Age (years)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Female (&#x00025;)</td><td align="left" rowspan="1" colspan="1">Male (&#x00025;)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">Range</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TB not affected controls (TBNA)</td><td align="left" rowspan="1" colspan="1">188</td><td align="left" rowspan="1" colspan="1">88 (46.8)</td><td align="left" rowspan="1" colspan="1">100 (53.1)</td><td align="left" rowspan="1" colspan="1">28.10</td><td align="left" rowspan="1" colspan="1">6&#x02013;70</td></tr><tr><td align="left" rowspan="1" colspan="1">TB affected patients (TBA)</td><td align="left" rowspan="1" colspan="1">188</td><td align="left" rowspan="1" colspan="1">118 (62.7)</td><td align="left" rowspan="1" colspan="1">70 (37.2)</td><td align="left" rowspan="1" colspan="1">33.40</td><td align="left" rowspan="1" colspan="1">7&#x02013;81</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Pulmonary TB (PTB)</bold></td><td align="left" rowspan="1" colspan="1">111</td><td align="left" rowspan="1" colspan="1">65 (58.5)</td><td align="left" rowspan="1" colspan="1">46 (41.4)</td><td align="left" rowspan="1" colspan="1">32.0</td><td align="left" rowspan="1" colspan="1">10&#x02013;81</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary minimal (PMN)</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">9 (47.3)</td><td align="left" rowspan="1" colspan="1">10 (52.6)</td><td align="left" rowspan="1" colspan="1">36.3</td><td align="left" rowspan="1" colspan="1">15&#x02013;81</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary moderate (PMD)</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">37 (58.7)</td><td align="left" rowspan="1" colspan="1">26 (41.2)</td><td align="left" rowspan="1" colspan="1">33.0</td><td align="left" rowspan="1" colspan="1">13&#x02013;70</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary advance (PAD)</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">19 (65.5)</td><td align="left" rowspan="1" colspan="1">10 (34.4)</td><td align="left" rowspan="1" colspan="1">26.2</td><td align="left" rowspan="1" colspan="1">10&#x02013;69</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Extra pulmonary TB (ETB)</bold></td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">47 (70.1)</td><td align="left" rowspan="1" colspan="1">20 (35.0)</td><td align="left" rowspan="1" colspan="1">34.5</td><td align="left" rowspan="1" colspan="1">7&#x02013;80</td></tr><tr><td align="left" rowspan="1" colspan="1">Disseminated TB (DTB)</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">12 (60.0)</td><td align="left" rowspan="1" colspan="1">8 (40.0)</td><td align="left" rowspan="1" colspan="1">37.3</td><td align="left" rowspan="1" colspan="1">16&#x02013;80</td></tr><tr><td align="left" rowspan="1" colspan="1">Localized TB (LTB)</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">35 (74.5)</td><td align="left" rowspan="1" colspan="1">12 (25.5)</td><td align="left" rowspan="1" colspan="1">33.3</td><td align="left" rowspan="1" colspan="1">7&#x02013;75</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label/><p><bold>Note:</bold> Patient stratification is as given in <xref ref-type="sec" rid="s4">Materials and Methods</xref>. Abbreviations for groups are given in brackets. TBA included 10 previously treated patients.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b"><title>Relationship of genotype and phenotype of IFN&#x003b3; (&#x0002b;874<italic>T</italic><sup>hi</sup>&#x02192;<italic>A</italic><sup>lo</sup>) and IL10 (&#x02212;1082 <italic>G</italic><sup>lo</sup>&#x02192;<italic>A</italic><sup>hi</sup>) in TBNA</title><p><xref ref-type="fig" rid="pone-0004778-g001">Figure 1</xref> shows the relationship of cytokine secretion in response to mycobacterial antigen stimulation with different genotypes IFN&#x003b3; (&#x0002b;874 <italic>T<sup>hi</sup></italic>&#x02192;<italic>A</italic><sup>lo</sup>) and IL10 (&#x02212;1082 <italic>G</italic><sup>lo</sup>&#x02192;<italic>A</italic><sup>hi</sup>).We found IFN&#x003b3; <italic>TT</italic> and IL10 <italic>AA</italic> to be the high producer phenotype in response to mycobacterial antigens. We next looked at the frequency of these genotypes in association with disease severity.</p><fig id="pone-0004778-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004778.g001</object-id><label>Figure 1</label><caption><title>Relationship of IFN&#x003b3; and IL10 SNPs with mycobacterial antigen induced cytokine secretion.</title><p>Whole blood from TB not affected (TBNA) Tuberculin skin test positive donors was stimulated with <italic>M. tuberculosis</italic> culture filtrate (CF) proteins &#x0005b;5 &#x000b5;g/ml&#x0005d; and supernatants tested at 2 days for IL10 secretion and day 5 for IFN&#x003b3; secretion using ELISA method as described in <xref ref-type="sec" rid="s4">material and methods</xref>. Results are expressed as pg/ml after deducting secretion in un-stimulated whole blood.</p></caption><graphic xlink:href="pone.0004778.g001"/></fig></sec><sec id="s2c"><title>Distinct IFN&#x003b3; &#x0002b;874 but not IL10 &#x02212;1082 genotype SNPs are associated with different disease sites and not with TB susceptibility</title><p>Cytokine genotypes and alleles frequencies in all patient groups were compared with healthy controls (<xref ref-type="table" rid="pone-0004778-t003">Tables 3</xref> &#x00026; <xref ref-type="table" rid="pone-0004778-t004">4</xref>). IFN&#x003b3; &#x0002b;874<italic>T</italic>&#x02192;<italic>A</italic> genotype distribution was in Hardy-Weinberg equilibrium for both patients and controls (TBA; <italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.607 and TBNA; <italic>p</italic>&#x0200a;&#x0003d;&#x0200a;1.0). On the other hand, IL-10 &#x02212;1082G&#x02192;A polymorphism showed deviation from HWE due to excess of heterozygosity (TBA and TBNA; <italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.00004). Cases and controls were compared using &#x003c7;<sup>2</sup>, odds ratios (OR) and their confidence intervals, (95&#x00025; CI). A <italic>p</italic> value of &#x0003c;0.05 was considered significant. Different cytokine genotypes and alleles showed distinct associations with different disease types as described below.</p><p>IFN&#x003b3; &#x0002b;874 <italic>TT</italic> genotype showed significant association with PTB (&#x003c7;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;6.05, <italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.034) (<xref ref-type="table" rid="pone-0004778-t003">Table 3</xref>). This association was restricted to the T allele (<xref ref-type="table" rid="pone-0004778-t004">Table 4</xref>). In terms of disease severity in the lung this association was restricted to PMN and PMD and was not seen with PAD. Similarly, no association was observed with ETB or stratified ETB on the basis of disease severity (DTB <italic>vs.</italic> LTB). When we compared healthy controls with latent infection (TST&#x0002b;) similar and much more marked effect of IFN&#x003b3; &#x0002b;874 <italic>TT</italic> genotype was observed (<xref ref-type="table" rid="pone-0004778-t003">Table 3</xref>). Therefore, genotype associations were not only different according to disease site (PTB <italic>vs.</italic> ETB) but there was a distinct difference between severity within a disease site (PMD <italic>vs.</italic> PAD). These results therefore suggest that it is inappropriate to pool tuberculosis patient with differing sites and even severity within individual sites.</p><p><xref ref-type="table" rid="pone-0004778-t003">Table 3</xref> also shows the frequency of IL10 &#x02212;1082 genotype in relation to disease site as well as disease severity. Neither IL10 &#x02212;1082 genotype nor alleles (<xref ref-type="table" rid="pone-0004778-t004">Table 4</xref>) show any association in relation to either site or severity of tuberculosis. The <italic>p</italic> values were similar when patients were compared with TST&#x0002b; controls (<xref ref-type="table" rid="pone-0004778-t004">Table 4</xref>). There was an overrepresentation of the IL10 &#x02212;1082 heterozygous genotype <italic>GA</italic> in both controls and PTB as well as ETB. Linkage disequilibrium is not uncommon in consangious populations such as where the study is being conducted. <xref ref-type="bibr" rid="pone.0004778-Mehdi1">&#x0005b;17&#x0005d;</xref></p></sec><sec id="s2d"><title>Multiloci genotype association with risk of disease severity across the tuberculosis disease spectrum</title><p>We have previously shown that IFN&#x003b3;/IL10 ratio is a critical determinant of disease severity <xref ref-type="bibr" rid="pone.0004778-Jamil1">&#x0005b;16&#x0005d;</xref>. Since both cytokines (IFN&#x003b3;, IL10) showed distinct associations with different sites and severity of TB, we also assessed if genotype combinations for these two cytokines may contribute to increased risk of TB with respect to site or severity. There were nine possible combinations. Only significant results are shown in <xref ref-type="table" rid="pone-0004778-t005">Table 5</xref>. As expected from previous analyses (<xref ref-type="table" rid="pone-0004778-t003">Table 3</xref>) there was a clear association of IFN&#x003b3; <italic>TT</italic><sup>hi</sup> with pulmonary disease while IFN&#x003b3; <italic>AA<sup>lo</sup></italic> was clearly associated with increased risk of PAD and DTB. The effect of IL10 genotype combination was much more evident with disease site rather than disease severity. IL10 <italic>GG</italic><sup>lo</sup> in combination with IFN&#x003b3; <italic>AA<sup>lo</sup></italic> was associated with the highest risk for DTB (OR&#x0200a;&#x0003d;&#x0200a;3.59; <italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.045). The results were similar when cases were compared with TST&#x0002b; controls.</p></sec></sec><sec id="s3"><title>Discussion</title><p>Although the effect of cytokine gene polymorphisms (SNPs) on tuberculosis disease sites or disease severity have been reported in different populations, our results for the first time show differential association of cytokine genotype combinations with either pulmonary or extra-pulmonary disease. We also report that in the lung compartment the high responder IL10 &#x02212;1082 <italic>AA</italic><sup>hi</sup> may play a critical role in limiting tissue damage in PTB. Because of careful characterization of disease in each of the group, we are able to show significant differences between groups and among groups. In addition, differences seen in both cytokines SNPs can be reconciled with their biological function. We feel that this is a very important issue despite small numbers in the stratified groups. When pulmonary patients are not stratified the sample size is sufficient for power of statistics. We have therefore given results for both pooled and stratified groups. There are very few studies, which relate genotype to phenotype. This is the strength of the current study.</p><p>There are considerable variations in allelic frequencies of cytokine gene polymorphisms in different populations <xref ref-type="bibr" rid="pone.0004778-Bagheri1">&#x0005b;18&#x0005d;</xref> and therefore it is not surprising that genetic polymorphisms associated with tuberculosis have yielded conflicting results in different ethnic groups <xref ref-type="bibr" rid="pone.0004778-Takiff1">&#x0005b;19&#x0005d;</xref>. IFN&#x003b3; polymorphism (&#x0002b;874 <italic>T</italic><sup>hi</sup>&#x02192;<italic>A</italic><sup>lo</sup>) is the most studied polymorphism in terms of association with tuberculosis disease sites and severity. However, the reports are conflicting in that <italic>A</italic> allele is more common in patients with TB and <italic>T</italic> alleles, more common in controls in Italian <xref ref-type="bibr" rid="pone.0004778-Lio1">&#x0005b;20&#x0005d;</xref>, South African <xref ref-type="bibr" rid="pone.0004778-Rossouw1">&#x0005b;21&#x0005d;</xref> Hong Kong Chinese <xref ref-type="bibr" rid="pone.0004778-Tso1">&#x0005b;22&#x0005d;</xref>and Spanish populations <xref ref-type="bibr" rid="pone.0004778-LopezMaderuelo1">&#x0005b;23&#x0005d;</xref>. In Turkey, one study reported no association <xref ref-type="bibr" rid="pone.0004778-Oral1">&#x0005b;24&#x0005d;</xref>, while a later study in the same population showed an association with the <italic>A</italic> allele <xref ref-type="bibr" rid="pone.0004778-Sallakci1">&#x0005b;25&#x0005d;</xref>. In Croatia <xref ref-type="bibr" rid="pone.0004778-Etokebe1">&#x0005b;26&#x0005d;</xref> an association with <italic>A</italic> allele was found only in microscopy and culture positive <italic>vs.</italic> negative TB patients. On the other hand, no association has been reported in Caucasians in Houston, Texas <xref ref-type="bibr" rid="pone.0004778-Moran1">&#x0005b;27&#x0005d;</xref> and South Indian populations <xref ref-type="bibr" rid="pone.0004778-Vidyarani1">&#x0005b;28&#x0005d;</xref>. There is only one study in Colombia <xref ref-type="bibr" rid="pone.0004778-Henao1">&#x0005b;29&#x0005d;</xref> where an association of IFN&#x003b3; &#x0002b;874 <italic>T</italic> allele with the more localized pleural disease has been observed. Our results are in agreement with the latter study. We show that the effect of IFN&#x003b3; <italic>T</italic> allele in TB affected patients is restricted to pulmonary patients with minimal/ moderate disease increasing the risk by 2&#x02013;3 folds (<xref ref-type="table" rid="pone-0004778-t004">Table 4</xref>). Both our study and the Colombian study show a much more marked association with the more protective form of tuberculosis. Some of the differences could be due to the influence of other genes linked to tuberculosis disease susceptibility <xref ref-type="bibr" rid="pone.0004778-Pravica1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004778-Vidyarani1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004778-Cooke1">&#x0005b;30&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0004778-Sahiratmadja1">&#x0005b;32&#x0005d;</xref>. As shown in our study, the presence of high responder IL10 &#x02212;1082 <italic>AA</italic><sup>hi</sup> may limit lung tissue damage when associated with IFN&#x003b3; <italic>TT</italic><sup>hi</sup>. Turner has reported <italic>AA</italic> to be a low producer phenotype in response to mitogenic (ConA) stimulus <xref ref-type="bibr" rid="pone.0004778-Turner1">&#x0005b;33&#x0005d;</xref>. Mycobacterial antigens are potent stimulators of macrophages <xref ref-type="bibr" rid="pone.0004778-Hussain1">&#x0005b;34&#x0005d;</xref> while Con A is primarily a T cell stimulator <xref ref-type="bibr" rid="pone.0004778-Turner1">&#x0005b;33&#x0005d;</xref>. Therefore, it is possible that different stimuli may result in differential transcription of the same gene. For the current study we considered mycobacterial antigens to be the more appropriate stimulus.</p><p>A similar discrepancy is observed with IL10 (&#x02212;1082 <italic>G</italic><sup>lo</sup>&#x02192;<italic>A</italic><sup>hi</sup>) where no associations were reported in Gambian <xref ref-type="bibr" rid="pone.0004778-Bellamy1">&#x0005b;35&#x0005d;</xref>, Korean <xref ref-type="bibr" rid="pone.0004778-Shin1">&#x0005b;36&#x0005d;</xref> and Spanish <xref ref-type="bibr" rid="pone.0004778-LopezMaderuelo1">&#x0005b;23&#x0005d;</xref> populations. An association of <italic>A</italic> allele was observed in Italian (Sicilian) <xref ref-type="bibr" rid="pone.0004778-Scola1">&#x0005b;37&#x0005d;</xref> population, and <italic>GA</italic> heterozygosity was associated with pulmonary TB in Cambodia <xref ref-type="bibr" rid="pone.0004778-Delgado1">&#x0005b;38&#x0005d;</xref>. Our results indicate that the homozygous <italic>GG</italic><sup>lo</sup> increases the risk of DTB when it is associated with IFN&#x003b3; &#x0002b;874 <italic>AA</italic><sup>lo</sup> phenotype (OR&#x0200a;&#x0003d;&#x0200a;3.59; p&#x0200a;&#x0003d;&#x0200a;0.045). This is consistent with the low levels of mycobacterial stimulated IFN&#x003b3; and IL10 from DTB <xref ref-type="bibr" rid="pone.0004778-Hussain2">&#x0005b;39&#x0005d;</xref>. We have observed an overrepresentation of <italic>GA</italic> heterozygous genotype in our study groups and may increase the risk of PMN when associated with IFN&#x003b3; <italic>AA</italic><sup>lo</sup> (<xref ref-type="table" rid="pone-0004778-t005">Table 5</xref>). The frequency of <italic>GA</italic> heterozygosity is highly variable in different populations ranging from 82.5&#x00025; in Iranian population to 5&#x00025; in Singapore Chinese <xref ref-type="bibr" rid="pone.0004778-Bagheri1">&#x0005b;18&#x0005d;</xref>. Our results (70.2&#x00025;) are closer to the Iranian population frequency. We further confirmed PCR amplified product by sequencing which also gave the expected SNP sequences for both IFN&#x003b3; and IL10 genotypes. Therefore, it is difficult to attribute the inflation in <italic>GA</italic> heterozygosity to artifacts in genotyping methodology as most studies have reported widely differing frequencies using ARMS PCR <xref ref-type="bibr" rid="pone.0004778-Bagheri1">&#x0005b;18&#x0005d;</xref>. It is not unexpected to find linkage disequilibrium in consangious population such as the setting in which this study was conducted <xref ref-type="bibr" rid="pone.0004778-Mehdi1">&#x0005b;17&#x0005d;</xref>. Further population-based studies are needed to address this issue.</p><p>Nevertheless, a consensus seems to be emerging in that the combined effect of several cytokine SNPs may play a more crucial role in disease severity <xref ref-type="bibr" rid="pone.0004778-Henao1">&#x0005b;29&#x0005d;</xref>. These results also substantiate our earlier report <xref ref-type="bibr" rid="pone.0004778-Jamil1">&#x0005b;16&#x0005d;</xref> that IFN&#x003b3;/IL10 ratio may be the critical determinant of clinical severity in both pulmonary and extra-pulmonary tuberculosis. A meta analyses recently published reinforces the critical importance of IFN&#x003b3; &#x0002b;874 T/A as a genetic marker for TB resistance <xref ref-type="bibr" rid="pone.0004778-Pacheco1">&#x0005b;9&#x0005d;</xref>, while IL10 indeed had some specific effect on TB determining the disease form and severity and not with susceptibility per se. Our results are consistent with these findings.</p><p>If the rationale for analyzing cytokine gene polymorphism is to understand the pathogenesis of human disease, to identify potential markers of susceptibility or disease severity, responder <italic>vs.</italic> non-responders in therapeutic and vaccine trials, and to design novel strategies for intervention in high-risk groups, then the diversity of genetic associations warrants that such analyses are carried out in indigenous population. Our results further highlight the importance of stratification of patients in relation to disease severity, which otherwise mask the significance of associations in combined groups.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Subject studied</title><p>Gene polymorphisms were analyzed in 376 donors (TB not affected, TBNA&#x0200a;&#x0003d;&#x0200a;188 and TB affected, TBA&#x0200a;&#x0003d;&#x0200a;188). <xref ref-type="table" rid="pone-0004778-t001">Table 1</xref> shows the breakdown of TB patients in terms of clinical severity: WHO guidelines for disease classification for non HIV related tuberculosis was adopted <xref ref-type="bibr" rid="pone.0004778-Jamil1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004778-Maher1">&#x0005b;40&#x0005d;</xref> as follows. DTB (N&#x0200a;&#x0003d;&#x0200a;20) had involvement of two or more sites with primary focus as meninges (N&#x0200a;&#x0003d;&#x0200a;3), spinal (N&#x0200a;&#x0003d;&#x0200a;1), intestinal (N&#x0200a;&#x0003d;&#x0200a;11), splenic (N&#x0200a;&#x0003d;&#x0200a;3) or miliary (N&#x0200a;&#x0003d;&#x0200a;4) with or without lung involvement. PTB (N&#x0200a;&#x0003d;&#x0200a;111) had involvement of lung parenchyma exclusively. LTB (N&#x0200a;&#x0003d;&#x0200a;47) included TB restricted to one site without lung involvement (lymph nodes&#x0200a;&#x0003d;&#x0200a;29, peripheral joints&#x0200a;&#x0003d;&#x0200a;9, pleural&#x0200a;&#x0003d;&#x0200a;8 and endobronchial&#x0200a;&#x0003d;&#x0200a;1). Patients were included in the study if they were positive by one or more of the following criteria: microscopy, culture, histology, imaging (chest&#x000d7;rays for pulmonary patients and miliary involvement, CT scans for abdominal and skeletal and splenic involvement, MRI for meninges, or definitive clinical response (<xref ref-type="table" rid="pone-0004778-t002">Table 2</xref>).</p><table-wrap id="pone-0004778-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004778.t002</object-id><label>Table 2</label><caption><title>Diagnostic modality used for confirmation of tuberculosis.</title></caption><graphic id="pone-0004778-t002-2" xlink:href="pone.0004778.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004778-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Disease<xref ref-type="table-fn" rid="nt103">&#x0002a;</xref> category</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">&#x00025; (TST&#x02265;10 mm)</td><td align="left" rowspan="1" colspan="1">Microscopy</td><td align="left" rowspan="1" colspan="1">Culture</td><td align="left" rowspan="1" colspan="1">Histology</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="nt104">&#x000b6;</xref>Imaging</td><td align="left" rowspan="1" colspan="1">Response to treatment</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TBNA</td><td align="left" rowspan="1" colspan="1">188</td><td align="left" rowspan="1" colspan="1">71</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary</td><td align="left" rowspan="1" colspan="1">111</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Disseminated</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Localized</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">13</td></tr></tbody></table><table-wrap-foot><fn id="nt102"><label/><p>Note: Primary diagnostic modality used diagnosis of tuberculosis.</p></fn><fn id="nt103"><label>&#x0002a;</label><p>Criteria for disease category given in <xref ref-type="sec" rid="s4">material and methods</xref>.</p></fn><fn id="nt104"><label>&#x000b6;</label><p>Imaging tests included chest&#x000d7;rays for pulmonary patients, CT scan and or MRI for disseminated disease.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0004778-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004778.t003</object-id><label>Table 3</label><caption><title>Genotype frequencies in healthy controls and different clinical forms of tuberculosis (TB).</title></caption><graphic id="pone-0004778-t003-3" xlink:href="pone.0004778.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004778-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Genotypes</td><td align="left" rowspan="1" colspan="1">TBNA (188)</td><td align="left" rowspan="1" colspan="1">TBA (188)</td><td align="left" rowspan="1" colspan="1">PTB (111)</td><td align="left" rowspan="1" colspan="1">PMN (19)</td><td align="left" rowspan="1" colspan="1">PMD (63)</td><td align="left" rowspan="1" colspan="1">PAD (29)</td><td align="left" rowspan="1" colspan="1">ETB (67)</td><td align="left" rowspan="1" colspan="1">DTB (20)</td><td align="left" rowspan="1" colspan="1">LTB (47)</td></tr></thead><tbody><tr><td colspan="10" align="left" rowspan="1"><bold>IFN-&#x003b3; (&#x0002b;874)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TT</bold></td><td align="left" rowspan="1" colspan="1">25 (13.3)</td><td align="left" rowspan="1" colspan="1">39 (20.74)</td><td align="left" rowspan="1" colspan="1">27 (24.32)</td><td align="left" rowspan="1" colspan="1">8 (42.11)</td><td align="left" rowspan="1" colspan="1">16 (25.4)</td><td align="left" rowspan="1" colspan="1">3 (10.34)</td><td align="left" rowspan="1" colspan="1">12 (17.91)</td><td align="left" rowspan="1" colspan="1">3 (15.00)</td><td align="left" rowspan="1" colspan="1">9 (19.15)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TA</bold></td><td align="left" rowspan="1" colspan="1">87 (46.28)</td><td align="left" rowspan="1" colspan="1">83 (44.15)</td><td align="left" rowspan="1" colspan="1">47 (42.34)</td><td align="left" rowspan="1" colspan="1">6 (31.58)</td><td align="left" rowspan="1" colspan="1">28 (44.44)</td><td align="left" rowspan="1" colspan="1">13 (44.83)</td><td align="left" rowspan="1" colspan="1">30 (44.78)</td><td align="left" rowspan="1" colspan="1">8 (40.00)</td><td align="left" rowspan="1" colspan="1">22 (46.80)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>AA</bold></td><td align="left" rowspan="1" colspan="1">76 (40.43)</td><td align="left" rowspan="1" colspan="1">66 (35.11)</td><td align="left" rowspan="1" colspan="1">37 (33.33)</td><td align="left" rowspan="1" colspan="1">5 (26.32)</td><td align="left" rowspan="1" colspan="1">19 (30.16)</td><td align="left" rowspan="1" colspan="1">13 (44.83)</td><td align="left" rowspan="1" colspan="1">25 (37.31)</td><td align="left" rowspan="1" colspan="1">9 (45.00)</td><td align="left" rowspan="1" colspan="1">16 (34.04)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>&#x003c7;<sup>2</sup></italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.86</td><td align="left" rowspan="1" colspan="1">6.05</td><td align="left" rowspan="1" colspan="1">10.69</td><td align="left" rowspan="1" colspan="1">5.58</td><td align="left" rowspan="1" colspan="1">0.30</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">0.29</td><td align="left" rowspan="1" colspan="1">1.28</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Corrected </bold><bold><italic>p</italic></bold><bold>&#x0200a;&#x0003d;&#x0200a;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.08</td><td align="left" rowspan="1" colspan="1"><bold>0.034</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.012</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.029</bold></td><td align="left" rowspan="1" colspan="1">0.588</td><td align="left" rowspan="1" colspan="1">0.433</td><td align="left" rowspan="1" colspan="1">0.859</td><td align="left" rowspan="1" colspan="1">0.278</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Corrected </bold><bold><italic>p</italic></bold><bold>&#x0200a;&#x0003d;&#x0200a;</bold></td><td align="left" rowspan="1" colspan="1"><bold>TBNA TST&#x0002b; (133)</bold></td><td align="left" rowspan="1" colspan="1">0.064</td><td align="left" rowspan="1" colspan="1"><bold>0.007</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.029</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.008</bold></td><td align="left" rowspan="1" colspan="1">0.780</td><td align="left" rowspan="1" colspan="1">0.649</td><td align="left" rowspan="1" colspan="1">0.857</td><td align="left" rowspan="1" colspan="1">0.495</td></tr><tr><td colspan="10" align="left" rowspan="1"><bold>IL-10 (&#x02212;1082)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>GG</bold></td><td align="left" rowspan="1" colspan="1">20 (10.64)</td><td align="left" rowspan="1" colspan="1">27(14.36)</td><td align="left" rowspan="1" colspan="1">19 (17.12)</td><td align="left" rowspan="1" colspan="1">4 (21.05)</td><td align="left" rowspan="1" colspan="1">7 (11.1)</td><td align="left" rowspan="1" colspan="1">8 (27.59)</td><td align="left" rowspan="1" colspan="1">8 (11.94)</td><td align="left" rowspan="1" colspan="1">4 (20.00)</td><td align="left" rowspan="1" colspan="1">4 (8.51)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>GA</bold></td><td align="left" rowspan="1" colspan="1">136 (72.34)</td><td align="left" rowspan="1" colspan="1">132 (70.21)</td><td align="left" rowspan="1" colspan="1">71 (63.96)</td><td align="left" rowspan="1" colspan="1">11 (57.893)</td><td align="left" rowspan="1" colspan="1">46(73.02)</td><td align="left" rowspan="1" colspan="1">14 (48.25)</td><td align="left" rowspan="1" colspan="1">51 (76.12)</td><td align="left" rowspan="1" colspan="1">12 (60.00)</td><td align="left" rowspan="1" colspan="1">39 (82.98)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>AA</bold></td><td align="left" rowspan="1" colspan="1">32 (17.02)</td><td align="left" rowspan="1" colspan="1">29 (15.43)</td><td align="left" rowspan="1" colspan="1">21 (18.92)</td><td align="left" rowspan="1" colspan="1">4 (21.05)</td><td align="left" rowspan="1" colspan="1">10 (15.89)</td><td align="left" rowspan="1" colspan="1">7 (24.14)</td><td align="left" rowspan="1" colspan="1">8 (11.94)</td><td align="left" rowspan="1" colspan="1">4 (20.00)</td><td align="left" rowspan="1" colspan="1">4 (8.51)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>&#x003c7;<sup>2</sup></italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.25</td><td align="left" rowspan="1" colspan="1">3.09</td><td align="left" rowspan="1" colspan="1">2.20</td><td align="left" rowspan="1" colspan="1">0.05</td><td align="left" rowspan="1" colspan="1">8.41</td><td align="left" rowspan="1" colspan="1">0.98</td><td align="left" rowspan="1" colspan="1">1.85</td><td align="left" rowspan="1" colspan="1">2.52</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Corrected </bold><bold><italic>p</italic></bold><bold>&#x0200a;&#x0003d;&#x0200a;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.33</td><td align="left" rowspan="1" colspan="1">0.489</td><td align="left" rowspan="1" colspan="1">0.621</td><td align="left" rowspan="1" colspan="1">0.831</td><td align="left" rowspan="1" colspan="1">0.374</td><td align="left" rowspan="1" colspan="1">0.384</td><td align="left" rowspan="1" colspan="1">0.612</td><td align="left" rowspan="1" colspan="1">0.437</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Corrected </bold><bold><italic>p</italic></bold><bold>&#x0200a;&#x0003d;&#x0200a;</bold></td><td align="left" rowspan="1" colspan="1"><bold>TBNA TST&#x0002b; (133)</bold></td><td align="left" rowspan="1" colspan="1">0.435</td><td align="left" rowspan="1" colspan="1">0.767</td><td align="left" rowspan="1" colspan="1">0.945</td><td align="left" rowspan="1" colspan="1">0.867</td><td align="left" rowspan="1" colspan="1">0.341</td><td align="left" rowspan="1" colspan="1">0.330</td><td align="left" rowspan="1" colspan="1">0.582</td><td align="left" rowspan="1" colspan="1">0.357</td></tr></tbody></table><table-wrap-foot><fn id="nt105"><label/><p>Note: Patient stratification is given in <xref ref-type="sec" rid="s4">Materials and Methods</xref>. N for each group given in brackets. Abbreviations used as in <xref ref-type="table" rid="pone-0004778-t001">Table 1</xref>. Number (frequency) of genotypes is indicated. Pearson chi analysis was carried to determine the significance of differences.</p></fn><fn id="nt106"><label/><p>All significant p values are indicated in bold. P approaching significance is given in italics. <italic>p</italic>&#x0003c;0.05 is considered significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0004778-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004778.t004</object-id><label>Table 4</label><caption><title>Differences in allele frequencies in healthy controls and tuberculosis patients</title></caption><graphic id="pone-0004778-t004-4" xlink:href="pone.0004778.t004"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004778-t004-4"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">IFN-&#x003b3; (&#x0002b;874 T<sup>hi</sup>&#x02192;A<sup>lo</sup>)</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">chi-value</td><td align="left" rowspan="1" colspan="1">corrected <italic>p</italic>&#x0200a;&#x0003d;&#x0200a;</td><td align="left" rowspan="1" colspan="1">OR</td><td align="left" rowspan="1" colspan="1">95&#x00025; CI (lower)</td><td align="left" rowspan="1" colspan="1">95&#x00025; CI (upper)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>TBNA</bold></td><td align="left" rowspan="1" colspan="1"><bold>188</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TBA</bold></td><td align="left" rowspan="1" colspan="1"><bold>188</bold></td><td align="left" rowspan="1" colspan="1">3.20</td><td align="left" rowspan="1" colspan="1">0.074</td><td align="left" rowspan="1" colspan="1">1.31</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">1.75</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>PTB</bold></td><td align="left" rowspan="1" colspan="1"><bold>111</bold></td><td align="left" rowspan="1" colspan="1">4.78</td><td align="left" rowspan="1" colspan="1"><bold>0.029</bold></td><td align="left" rowspan="1" colspan="1">1.46</td><td align="left" rowspan="1" colspan="1">1.04</td><td align="left" rowspan="1" colspan="1">2.04</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>PMN</bold></td><td align="left" rowspan="1" colspan="1"><bold>19</bold></td><td align="left" rowspan="1" colspan="1">6.72</td><td align="left" rowspan="1" colspan="1"><bold>0.01</bold></td><td align="left" rowspan="1" colspan="1">2.4</td><td align="left" rowspan="1" colspan="1">1.22</td><td align="left" rowspan="1" colspan="1">4.72</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>PMD</bold></td><td align="left" rowspan="1" colspan="1"><bold>63</bold></td><td align="left" rowspan="1" colspan="1">4.95</td><td align="left" rowspan="1" colspan="1"><bold>0.026</bold></td><td align="left" rowspan="1" colspan="1">1.59</td><td align="left" rowspan="1" colspan="1">1.05</td><td align="left" rowspan="1" colspan="1">2.38</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>PAD</bold></td><td align="left" rowspan="1" colspan="1"><bold>29</bold></td><td align="left" rowspan="1" colspan="1">0.29</td><td align="left" rowspan="1" colspan="1">0.587</td><td align="left" rowspan="1" colspan="1">0.85</td><td align="left" rowspan="1" colspan="1">0.47</td><td align="left" rowspan="1" colspan="1">1.53</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ETB</bold></td><td align="left" rowspan="1" colspan="1"><bold>67</bold></td><td align="left" rowspan="1" colspan="1">0.46</td><td align="left" rowspan="1" colspan="1">0.50</td><td align="left" rowspan="1" colspan="1">1.15</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">1.72</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>DTB</bold></td><td align="left" rowspan="1" colspan="1"><bold>20</bold></td><td align="left" rowspan="1" colspan="1">0.032</td><td align="left" rowspan="1" colspan="1">0.858</td><td align="left" rowspan="1" colspan="1">0.94</td><td align="left" rowspan="1" colspan="1">0.47</td><td align="left" rowspan="1" colspan="1">1.86</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>LTB</bold></td><td align="left" rowspan="1" colspan="1"><bold>47</bold></td><td align="left" rowspan="1" colspan="1">1.12</td><td align="left" rowspan="1" colspan="1">0.274</td><td align="left" rowspan="1" colspan="1">1.29</td><td align="left" rowspan="1" colspan="1">0.82</td><td align="left" rowspan="1" colspan="1">2.05</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>IL-10 (&#x02212;1082 G<sup>lo</sup></bold>&#x02192;<bold>A<sup>hi</sup>)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TBNA</bold></td><td align="left" rowspan="1" colspan="1"><bold>188</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TBA</bold></td><td align="left" rowspan="1" colspan="1"><bold>188</bold></td><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">0.48</td><td align="left" rowspan="1" colspan="1">1.11</td><td align="left" rowspan="1" colspan="1">0.83</td><td align="left" rowspan="1" colspan="1">1.48</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>PTB</bold></td><td align="left" rowspan="1" colspan="1"><bold>111</bold></td><td align="left" rowspan="1" colspan="1">0.29</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">1.01</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">1.54</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>PMN</bold></td><td align="left" rowspan="1" colspan="1"><bold>19</bold></td><td align="left" rowspan="1" colspan="1">0.14</td><td align="left" rowspan="1" colspan="1">0.708</td><td align="left" rowspan="1" colspan="1">1.14</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">2.22</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>PMD</bold></td><td align="left" rowspan="1" colspan="1"><bold>63</bold></td><td align="left" rowspan="1" colspan="1">0.025</td><td align="left" rowspan="1" colspan="1">0.875</td><td align="left" rowspan="1" colspan="1">1.03</td><td align="left" rowspan="1" colspan="1">0.69</td><td align="left" rowspan="1" colspan="1">1.55</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>PAD</bold></td><td align="left" rowspan="1" colspan="1"><bold>29</bold></td><td align="left" rowspan="1" colspan="1">0.49</td><td align="left" rowspan="1" colspan="1">0.486</td><td align="left" rowspan="1" colspan="1">1.22</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2.12</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ETB</bold></td><td align="left" rowspan="1" colspan="1"><bold>67</bold></td><td align="left" rowspan="1" colspan="1">0.036</td><td align="left" rowspan="1" colspan="1">0.85</td><td align="left" rowspan="1" colspan="1">1.04</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">1.54</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>DTB</bold></td><td align="left" rowspan="1" colspan="1"><bold>20</bold></td><td align="left" rowspan="1" colspan="1">0.15</td><td align="left" rowspan="1" colspan="1">0.701</td><td align="left" rowspan="1" colspan="1">1.14</td><td align="left" rowspan="1" colspan="1">0.59</td><td align="left" rowspan="1" colspan="1">2.18</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>LTB</bold></td><td align="left" rowspan="1" colspan="1"><bold>47</bold></td><td align="left" rowspan="1" colspan="1">0.307</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">1.14</td><td align="left" rowspan="1" colspan="1">0.72</td><td align="left" rowspan="1" colspan="1">1.79</td></tr></tbody></table><table-wrap-foot><fn id="nt107"><label/><p>Note: Patient stratification is given in <xref ref-type="sec" rid="s4">material and methods</xref>. N for each group is given in brackets. Abbreviations used as in <xref ref-type="table" rid="pone-0004778-t001">Table 1</xref>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0004778-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004778.t005</object-id><label>Table 5</label><caption><title>Genotype combination in relation to disease severity.</title></caption><graphic id="pone-0004778-t005-5" xlink:href="pone.0004778.t005"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004778-t005-5"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">IFN&#x003b3;/IL10 genotypes</td><td align="left" rowspan="1" colspan="1">TBNA</td><td align="left" rowspan="1" colspan="1">PMN</td><td align="left" rowspan="1" colspan="1">PMD</td><td align="left" rowspan="1" colspan="1">PAD</td><td align="left" rowspan="1" colspan="1">DTB</td><td align="left" rowspan="1" colspan="1">LTB</td></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">188</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">47</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>TT/GG &#x00025;</bold></td><td align="left" rowspan="1" colspan="1">2.13</td><td align="left" rowspan="1" colspan="1">10.53</td><td align="left" rowspan="1" colspan="1">1.59</td><td align="left" rowspan="1" colspan="1">6.9</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.2</td></tr><tr><td align="left" rowspan="1" colspan="1">chi<sup>2</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6.66</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>corrected </bold><bold><italic>p</italic></bold><bold>&#x0200a;&#x0003d;&#x0200a;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>0.01</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>OR</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>6.06</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>(95&#x00025; CI)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>(1.30&#x02013;28.07)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TT/AA &#x00025;</bold></td><td align="left" rowspan="1" colspan="1">3.19</td><td align="left" rowspan="1" colspan="1">10.53</td><td align="left" rowspan="1" colspan="1">6.35</td><td align="left" rowspan="1" colspan="1">3.45</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">2.13</td></tr><tr><td align="left" rowspan="1" colspan="1">chi<sup>2</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4.92</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>corrected </bold><bold><italic>p</italic></bold><bold>&#x0200a;&#x0003d;&#x0200a;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>0.027</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>OR</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>3.99</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>(95&#x00025; CI)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>(1.08&#x02013;14.8)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TT/GA&#x00025;</bold></td><td align="left" rowspan="1" colspan="1">7.98</td><td align="left" rowspan="1" colspan="1">21.05</td><td align="left" rowspan="1" colspan="1">17.46</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">12.8</td></tr><tr><td align="left" rowspan="1" colspan="1">chi<sup>2</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6.82</td><td align="left" rowspan="1" colspan="1">4.4</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>corrected </bold><bold><italic>p</italic></bold><bold>&#x0200a;&#x0003d;&#x0200a;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>0.009</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.036</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">OR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>3.06</italic></td><td align="left" rowspan="1" colspan="1"><italic>2.50</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">(95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>(1.08&#x02013;7.28)</italic></td><td align="left" rowspan="1" colspan="1"><italic>(1.04&#x02013;6.1)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TA/GG &#x00025;</bold></td><td align="left" rowspan="1" colspan="1">5.85</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.76</td><td align="left" rowspan="1" colspan="1">6.9</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">2.13</td></tr><tr><td align="left" rowspan="1" colspan="1">chi<sup>2</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>corrected </bold><bold><italic>p</italic></bold><bold>&#x0200a;&#x0003d;&#x0200a;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>OR (95&#x00025; CI)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TA/AA &#x00025;</bold></td><td align="left" rowspan="1" colspan="1">5.32</td><td align="left" rowspan="1" colspan="1">10.53</td><td align="left" rowspan="1" colspan="1">6.35</td><td align="left" rowspan="1" colspan="1">6.9</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.2</td></tr><tr><td align="left" rowspan="1" colspan="1">chi<sup>2</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>corrected </bold><bold><italic>p</italic></bold><bold>&#x0200a;&#x0003d;&#x0200a;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>OR (95&#x00025; CI)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TA/GA &#x00025;</bold></td><td align="left" rowspan="1" colspan="1">35.11</td><td align="left" rowspan="1" colspan="1">21.05</td><td align="left" rowspan="1" colspan="1">33.33</td><td align="left" rowspan="1" colspan="1">31.03</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">40.4</td></tr><tr><td align="left" rowspan="1" colspan="1">chi2 (<italic>p</italic>-value)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4.86</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>corrected </bold><bold><italic>p</italic></bold><bold>&#x0200a;&#x0003d;&#x0200a;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>0.028</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>OR</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>0.40</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>(95&#x00025; CI)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>(0.26&#x02013;0.93)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>AA/GG &#x00025;</bold></td><td align="left" rowspan="1" colspan="1">2.66</td><td align="left" rowspan="1" colspan="1">10.53</td><td align="left" rowspan="1" colspan="1">4.76</td><td align="left" rowspan="1" colspan="1">13.79</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">2.13</td></tr><tr><td align="left" rowspan="1" colspan="1">chi<sup>2</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4.92</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">7.78</td><td align="left" rowspan="1" colspan="1">4.03</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>corrected </bold><bold><italic>p</italic></bold><bold>&#x0200a;&#x0003d;&#x0200a;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>0.027</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>0.005</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.045</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>OR</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>3.99</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>5.26</italic></td><td align="left" rowspan="1" colspan="1"><italic>3.59</italic></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>(95&#x00025; CI)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>(1.08&#x02013;14.79)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>(1.46&#x02013;18.9)</italic></td><td align="left" rowspan="1" colspan="1"><italic>(0.96&#x02013;13.47)</italic></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>AA/AA &#x00025;</bold></td><td align="left" rowspan="1" colspan="1">8.51</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3.17</td><td align="left" rowspan="1" colspan="1">13.79</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">2.13</td></tr><tr><td align="left" rowspan="1" colspan="1">chi<sup>2</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4.71</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>corrected </bold><bold><italic>p</italic></bold><bold>&#x0200a;&#x0003d;&#x0200a;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>0.03</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>OR</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>0.21</italic></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>(95&#x00025; CI)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>(0.04&#x02013;0.98)</italic></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>AA/GA &#x00025;</bold></td><td align="left" rowspan="1" colspan="1">39.26</td><td align="left" rowspan="1" colspan="1">15.79</td><td align="left" rowspan="1" colspan="1">22.2</td><td align="left" rowspan="1" colspan="1">17.24</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">29.7</td></tr><tr><td align="left" rowspan="1" colspan="1">chi<sup>2</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4.85</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4.06</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>corrected </bold><bold><italic>p</italic></bold><bold>&#x0200a;&#x0003d;&#x0200a;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>0.028</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>0.044</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>OR</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>0.45</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>0.50</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>(95&#x00025; CI)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>(0.24&#x02013;0.93)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>(0.25&#x02013;0.99)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>The control group consisted of healthy donors (TBNA&#x0200a;&#x0003d;&#x0200a;188) with no signs, symptoms or history of previous tuberculosis. Tuberculin skin tests (TST) positivity was assessed by administering five tuberculin units intracutaneously on the volar surface of the right arm. An induration of &#x02265;10 mm was used as a cut for positive responses (TST&#x0002b;) which is considered to be indicative of latent infection. The Aga Khan University Ethical Review Committee (ERC) approved the project. Written consent was obtained, for each participant or his or her guardians in case of minors after explaining the purpose of the study.</p></sec><sec id="s4b"><title>DNA Extraction</title><p>Five ml blood were collected in ACD (VWR Scientific, West Chester, PA, USA) tubes and kept frozen until use. Genomic DNA was extracted from frozen whole blood using Promega Wizard Genomic DNA Purification Kit (Promega Corporation Madison, WI, USA) according to the manufacturer's instructions. After extraction, DNA was quantified by spectrophotometery, checked for purity and stored at &#x02212;35&#x000b0;C until further analyses.</p></sec><sec id="s4c"><title>Molecular analysis</title><p>IFN&#x003b3; and IL10 genotype analyses were carried out using amplification refractory mutation system-PCR (ARMS-PCR) <xref ref-type="bibr" rid="pone.0004778-Perrey1">&#x0005b;41&#x0005d;</xref>. Primers used for the detection of SNPs were purchased from MWG-Biotech AG, (Ebersberg, Germany). Human growth hormone and &#x003b2; actin were used as internal controls to check the accuracy of PCR reactions. Amplified products were monitored by electrophoresis on agarose gel containing 10 mg/ml ethidium bromide. Product bands were visualized on a transiluminator and polaroid pictures were taken for interpretation.</p><p>Sequencing methodology was used as a second confirmatory method on a subset of samples to verify that correct alleles were being identified by ARMS-PCR. The primers used for sequencing analyses were IFN&#x003b3; Forward (<named-content content-type="gene">5&#x02032;-TAT GAT TCT GGC TAA GGA-3&#x02032;</named-content>), IFN&#x003b3; Reverse (<named-content content-type="gene">5&#x02032;-CCC CAA TGG TAC AGG TTT CT-3&#x02032;</named-content>) and IL-10 Forward (<named-content content-type="gene">5&#x02032;-TGT GGA AGG GGA AGG TG-3&#x02032;</named-content>), IL-10 Reverse (<named-content content-type="gene">5&#x02032;-TAA AAG ATG GGG TGG AAG AA-3&#x02032;</named-content>). These primers were designed using software Lasergene version 7.0 (DNAstar, Madison, WI, USA) and amplify a part of the gene that covers IFN&#x003b3; (&#x0002b;874T&#x02192;A) or IL10 (&#x02212;1082G&#x02192;A) SNPs to yield products size of 318 and 329 bp respectively. PCR products were purified with the QIAquick PCR purification kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Purified products were then sent to Macrogen for sequencing (Macrogen Inc, Seoul, Korea) with both forward and reverse primers. Sequencing results were analyzed by BLAST search of the GenBank database and EMBOSS pairwise alignment of the EMBL-EBI database. There was complete concordance between PCR based and sequence based analyses for homozygous as well as heterozygous genotypes (&#x0002b;874, <italic>TT</italic>&#x0200a;&#x0003d;&#x0200a;13; <italic>AA</italic>&#x0200a;&#x0003d;&#x0200a;9; &#x02212;1082, <italic>GG</italic>&#x0200a;&#x0003d;&#x0200a;6; <italic>GA</italic>&#x0200a;&#x0003d;&#x0200a;17).</p></sec><sec id="s4d"><title>Whole blood stimulation assays</title><p>Stimulated whole blood (WB) culture assay for assessing cytokine profiles have been described in detail previously <xref ref-type="bibr" rid="pone.0004778-Hussain1">&#x0005b;34&#x0005d;</xref>. Briefly, heparinized blood was diluted 1/11 with sterile RPMI 1640 tissue culture medium containing 100 units/ml of penicillin/100 &#x000b5;g/ml streptomycin and 2 mM L-glutamine (Sigma Chemical Co., St Louis, Mo). Diluted WB (900 &#x000b5;l/ well) were stimulated with MTB culture filtrate proteins &#x0005b;5 &#x000b5;g/m&#x0005d; in a 24-well tissue culture plates (Flow Laboratories, Irvine, Scotland) within 2 hours of collection. Supernatants were collected from the wells at varying intervals and stored as 4&#x000d7;200 &#x000b5;l aliquots at &#x02212;35&#x000b0;C.</p></sec><sec id="s4e"><title>Cytokine assessment</title><p>Cytokine (IFN&#x003b3; and IL10) in supernatants were assessed using pairs of monoclonal antibodies as described in detail previously <xref ref-type="bibr" rid="pone.0004778-Hussain2">&#x0005b;39&#x0005d;</xref>. Dose response curves were set up in each individual plate. Supernatants were serially diluted and optical density readings in the linear range of the dose response curve were used for calculating the concentrations. The final concentrations (pg/ml) were obtained after multiplying the values by dilutions at which the OD was read. The sensitivity and range of cytokine detection was 7.5&#x02013;1000 pg/ml and was comparable to that reported by the manufacturer.</p></sec><sec id="s4f"><title>Statistical Analysis</title><p>Allelic and genotypic frequencies and multi loci analysis were compared for all groups together and for individual patient and control groups. Computer software SPSS version 16.0 and Epi Info 2000 applications were used to carry out statistical analyses. Frequencies were compared between groups by Pearson chi-squared tests or Fisher's exact tests, when analyzing allelic frequencies lower than five to determine statistical significance differences between groups. Odds ratios (OR) with respective confidence intervals (95&#x00025; CI) for disease susceptibly were also calculated. Linear-by-linear test were used to determine the significance (corrected p values) of genotypes between TB groups and healthy controls. Multiple logistic regression analysis was applied, to determine the effect of age and sex with genotypes. Values of <italic>p</italic>&#x0003c;0.05 were considered significant for both Pearson and linear-by-linear &#x003c7;2 test. Hardy-Weinberg proportions were determined by applying the equation (p<sup>2</sup>&#x0002b;2pq&#x0002b;q<sup>2</sup>).</p></sec></sec></body><back><ack><p>We are grateful to Dr. Abbas Rehmani, Consultant Chest Physician, Rima Clinic, Karachi for providing blood samples from tuberculosis patients and Dr. Bushra Moiz of The Aga Khan University for providing samples from healthy donors. Excellent support for documentation of families by Miss Farida Talat and Ms Farzana Sohan (LHV) are gratefully acknowledged. We are grateful to Dr Philippe Frossard for critical comments on the manuscript. Excellent technical support by Mr. Mohammad Anwar for blood collection, and secretarial help by Ms Regina D'souza are gratefully acknowledged. We are also grateful to Ms Maqboola Dojki and Ms Firdaus Shahid for administrative support and Ms Nasira Asghar and Mr Iqbal Azam with help in statistical analysis. We acknowledge KIBGE, University of Karachi, for providing research and office space during Dr. Rabia Hussain's sabbatical during February&#x02013;April 2005.</p></ack><ref-list><title>References</title><ref id="pone.0004778-Akhtar1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akhtar</surname><given-names>S</given-names></name><name><surname>Carpenter</surname><given-names>TE</given-names></name><name><surname>Rathi</surname><given-names>SK</given-names></name></person-group><year>2007</year><article-title>A chain binomial model for intra-household spread of <italic>Mycobacterium tuberculosis</italic> in a low socio-economic setting in Pakistan.</article-title><source>Epidemiol Infect</source><volume>135</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">16740189</pub-id></citation></ref><ref id="pone.0004778-Dhingra1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhingra</surname><given-names>VK</given-names></name><name><surname>Rajpal</surname><given-names>S</given-names></name><name><surname>Aggarwal</surname><given-names>N</given-names></name><name><surname>Taneja</surname><given-names>DK</given-names></name></person-group><year>2004</year><article-title>Tuberculosis Trend among Household Contacts of TB Patients.</article-title><source>Indian J Comm Med</source><volume>29</volume><fpage>1</fpage><lpage>3</lpage></citation></ref><ref id="pone.0004778-Guwatudde1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guwatudde</surname><given-names>D</given-names></name><name><surname>Nakakeeto</surname><given-names>M</given-names></name><name><surname>Jones-Lopez</surname><given-names>EC</given-names></name><name><surname>Maganda</surname><given-names>A</given-names></name><name><surname>Chiunda</surname><given-names>A</given-names></name><etal/></person-group><year>2003</year><article-title>Tuberculosis in Household Contacts of Infectious Cases in Kampala, Uganda.</article-title><source>Am J Epidemiol</source><volume>158</volume><fpage>887</fpage><lpage>898</lpage><pub-id pub-id-type="pmid">14585767</pub-id></citation></ref><ref id="pone.0004778-Lemos1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lemos</surname><given-names>AC</given-names></name><name><surname>Matos</surname><given-names>ED</given-names></name><name><surname>Pedral-Sampaio</surname><given-names>DB</given-names></name><name><surname>Netto</surname><given-names>EM</given-names></name></person-group><year>2004</year><article-title>Risk of Tuberculosis among Household Contacts in Salvador, Bahia.</article-title><source>Braz J Infect Dis</source><volume>8</volume><fpage>424</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">15880233</pub-id></citation></ref><ref id="pone.0004778-Comstock1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Comstock</surname><given-names>G</given-names></name></person-group><year>1982</year><article-title>Epidemiology of Tuberculosis.</article-title><source>Am J Respir Dis</source><volume>125</volume><fpage>8</fpage><lpage>15</lpage></citation></ref><ref id="pone.0004778-Ferraz1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferraz</surname><given-names>JC</given-names></name><name><surname>Melo</surname><given-names>FB</given-names></name><name><surname>Albuquerque</surname><given-names>MF</given-names></name><name><surname>Montes</surname><given-names>C</given-names></name><name><surname>Abath</surname><given-names>FG</given-names></name></person-group><year>2006</year><article-title>Immune factors and immunoregulation in tuberculosis.</article-title><source>Braz J Med Biol Res</source><volume>39</volume><fpage>1387</fpage><lpage>1397</lpage><pub-id pub-id-type="pmid">17146551</pub-id></citation></ref><ref id="pone.0004778-Dorman1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorman</surname><given-names>SE</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Lammas</surname><given-names>D</given-names></name><name><surname>Heyne</surname><given-names>K</given-names></name><name><surname>van Dissel</surname><given-names>JT</given-names></name><etal/></person-group><year>2004</year><article-title>Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies.</article-title><source>Lancet</source><volume>364</volume><fpage>2113</fpage><lpage>2121</lpage><pub-id pub-id-type="pmid">15589309</pub-id></citation></ref><ref id="pone.0004778-Altare1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altare</surname><given-names>F</given-names></name><name><surname>Jouanguy</surname><given-names>E</given-names></name><name><surname>Lamhamedi-Cherradi</surname><given-names>S</given-names></name><name><surname>Fondaneche</surname><given-names>MC</given-names></name><name><surname>Fizame</surname><given-names>C</given-names></name><etal/></person-group><year>1998</year><article-title>A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFN gamma in a compound heterozygous child.</article-title><source>Am J Hum Genet</source><volume>62</volume><fpage>723</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">9497247</pub-id></citation></ref><ref id="pone.0004778-Pacheco1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pacheco</surname><given-names>AG</given-names></name><name><surname>Cardoso</surname><given-names>CC</given-names></name><name><surname>Moraes</surname><given-names>MO</given-names></name></person-group><year>2008</year><article-title>IFNG &#x0002b;874T/A, IL10 &#x02212;1082G/A and TNF &#x02212;308G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis study.</article-title><source>Hum Genet</source><volume>123</volume><fpage>477</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">18414898</pub-id></citation></ref><ref id="pone.0004778-Pravica1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pravica</surname><given-names>V</given-names></name><name><surname>Perrey</surname><given-names>C</given-names></name><name><surname>Stevens</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Hutchinson</surname><given-names>IV</given-names></name></person-group><year>2000</year><article-title>A single nucleotide polymorphism in the first intron of human interferon g gene: absolute correlation with a polymorphic C/A microsatellite marker of high interferon g production.</article-title><source>Human Immunology</source><volume>61</volume><fpage>863</fpage><lpage>866</lpage><pub-id pub-id-type="pmid">11053629</pub-id></citation></ref><ref id="pone.0004778-Rees1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname><given-names>LE</given-names></name><name><surname>Wood</surname><given-names>NA</given-names></name><name><surname>Gillespie</surname><given-names>KM</given-names></name><name><surname>Lai</surname><given-names>KN</given-names></name><name><surname>Gaston</surname><given-names>K</given-names></name><etal/></person-group><year>2002</year><article-title>The interleukin 10-1082 G/A polymorphism: allele frequency in different populations and functional significance.</article-title><source>Cell Mol Life Sci</source><volume>59</volume><fpage>560</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">11964134</pub-id></citation></ref><ref id="pone.0004778-Ates1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ates</surname><given-names>O</given-names></name><name><surname>Musellim</surname><given-names>B</given-names></name><name><surname>Ongen</surname><given-names>G</given-names></name><name><surname>Topal-Sarikaya</surname><given-names>A</given-names></name></person-group><year>2007</year><article-title>Interleukin-10 and Tumor Necrosis Factor-a Gene Polymorphism in Tuberculosis.</article-title><source>J Clin Immunol</source><fpage>1</fpage><lpage>5</lpage></citation></ref><ref id="pone.0004778-Oh1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>JH</given-names></name><name><surname>Yang</surname><given-names>CS</given-names></name><name><surname>Noh</surname><given-names>YK</given-names></name><name><surname>Kweon</surname><given-names>YM</given-names></name><name><surname>Jung</surname><given-names>S-S</given-names></name><etal/></person-group><year>2007</year><article-title>Polymorphism of interleukin-10 and tumour necrosis factor-a genes are associated with newly diagnosed and recurrent pulmonary tuberculosis.</article-title><source>Respirology</source><volume>12</volume><fpage>594</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">17587429</pub-id></citation></ref><ref id="pone.0004778-Flynn1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>JL</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Triebold</surname><given-names>KJ</given-names></name><name><surname>Dalton</surname><given-names>DK</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name><etal/></person-group><year>1993</year><article-title>An Essential role for Interferon gamma in resistance to Mycobacterium tuberculosis infection.</article-title><source>J Exp Med</source><volume>178</volume><fpage>2249</fpage><lpage>2254</lpage><pub-id pub-id-type="pmid">7504064</pub-id></citation></ref><ref id="pone.0004778-OGarra1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Garra</surname><given-names>A</given-names></name><name><surname>Vieira</surname><given-names>PL</given-names></name><name><surname>Vieira</surname><given-names>P</given-names></name><name><surname>Goldfeld</surname><given-names>AE</given-names></name></person-group><year>2004</year><article-title>IL-10 producing and naturally occurring CD4&#x0002b; Tregs: limiting collateral damage.</article-title><source>J Clin Invest</source><volume>114</volume><fpage>1372</fpage><lpage>1378</lpage><pub-id pub-id-type="pmid">15545984</pub-id></citation></ref><ref id="pone.0004778-Jamil1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jamil</surname><given-names>B</given-names></name><name><surname>Shahid</surname><given-names>F</given-names></name><name><surname>Hasan</surname><given-names>Z</given-names></name><name><surname>Nasir</surname><given-names>N</given-names></name><name><surname>Razzaki</surname><given-names>T</given-names></name><etal/></person-group><year>2007</year><article-title>Interferongamma/IL10 ratio defines the disease severity in pulmonary and extra pulmonary tuberculosis.</article-title><source>Tuberculosis (Edinb)</source><volume>87</volume><fpage>279</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">17532265</pub-id></citation></ref><ref id="pone.0004778-Mehdi1"><label>17</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Mehdi</surname><given-names>SQ</given-names></name><name><surname>Ayub</surname><given-names>Q</given-names></name><name><surname>Qamar</surname><given-names>R</given-names></name><name><surname>Mohyuddin</surname><given-names>A</given-names></name><name><surname>Mansoor</surname><given-names>A</given-names></name><etal/></person-group><year>2002</year><article-title>Perspectives on Human Genome Diversity within Pakistan using Y Chromosomal and Autosomal Microsatellite Markers.</article-title><person-group person-group-type="editor"><name><surname>Sener</surname><given-names>B</given-names></name></person-group><source>Biodiversity: Biomolecular Aspects of Biodiversity and Innovative Utilization</source><publisher-name>Kluwer Academic/Plenum Publishers</publisher-name><fpage>35</fpage><lpage>47</lpage></citation></ref><ref id="pone.0004778-Bagheri1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bagheri</surname><given-names>M</given-names></name><name><surname>Abdi-Rad</surname><given-names>I</given-names></name><name><surname>Omrani</surname><given-names>D</given-names></name><name><surname>Khalkhali</surname><given-names>HR</given-names></name></person-group><year>2006</year><article-title>Heterogeneity of cytokine single-nucleotide polymorphsims among the Iranian and in the other East-South Asian populations.</article-title><source>Transfusion Medicine</source><volume>16</volume><fpage>192</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">16764598</pub-id></citation></ref><ref id="pone.0004778-Takiff1"><label>19</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Takiff</surname><given-names>HE</given-names></name></person-group><year>2007</year><article-title>Host Genetics and Susceptibility.</article-title><person-group person-group-type="editor"><name><surname>Palomino</surname><given-names>JC</given-names></name><name><surname>Leao</surname><given-names>SC</given-names></name><name><surname>Ritacco</surname><given-names>V</given-names></name></person-group><source>Tuberculosis 2007 - From Basic Science to Patient Care</source><publisher-loc>Brazil</publisher-loc><fpage>207</fpage><lpage>262</lpage></citation></ref><ref id="pone.0004778-Lio1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lio</surname><given-names>D</given-names></name><name><surname>Marino</surname><given-names>V</given-names></name><name><surname>Serauto</surname><given-names>A</given-names></name><name><surname>Gioia</surname><given-names>V</given-names></name><name><surname>Scola</surname><given-names>L</given-names></name><etal/></person-group><year>2002</year><article-title>Genotype frequencies of the &#x0002b;874T&#x02212;&#x0003e;A single nucleotide polymorphism in the first intron of the interferon-gamma gene in a sample of Sicilian patients affected by tuberculosis.</article-title><source>Eur J Immunogenet</source><volume>29</volume><fpage>371</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">12358843</pub-id></citation></ref><ref id="pone.0004778-Rossouw1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rossouw</surname><given-names>M</given-names></name><name><surname>Nel</surname><given-names>HJ</given-names></name><name><surname>Cooke</surname><given-names>GS</given-names></name><name><surname>van Helden</surname><given-names>PD</given-names></name><name><surname>Hoal</surname><given-names>EG</given-names></name></person-group><year>2003</year><article-title>Association between tuberculosis and a polymorphic NFkappaB binding site in the interferon gamma gene.</article-title><source>Lancet</source><volume>361</volume><fpage>1871</fpage><lpage>1872</lpage><pub-id pub-id-type="pmid">12788577</pub-id></citation></ref><ref id="pone.0004778-Tso1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tso</surname><given-names>HW</given-names></name><name><surname>Ip</surname><given-names>WK</given-names></name><name><surname>Chong</surname><given-names>WP</given-names></name><name><surname>Tam</surname><given-names>CM</given-names></name><name><surname>Chiang</surname><given-names>AK</given-names></name><etal/></person-group><year>2005</year><article-title>Association of interferon gamma and interleukin 10 genes with tuberculosis in Hong Kong Chinese.</article-title><source>Genes Immun</source><volume>6</volume><fpage>358</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">15815688</pub-id></citation></ref><ref id="pone.0004778-LopezMaderuelo1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Maderuelo</surname><given-names>D</given-names></name><name><surname>Arnalich</surname><given-names>F</given-names></name><name><surname>Serantes</surname><given-names>R</given-names></name><name><surname>Gonzalez</surname><given-names>A</given-names></name><name><surname>Codoceo</surname><given-names>R</given-names></name><etal/></person-group><year>2003</year><article-title>Interferon-gamma and interleukin-10 gene polymorphisms in pulmonary tuberculosis 5691.</article-title><source>Am J Respir Crit Care Med</source><volume>167</volume><fpage>970</fpage><lpage>975</lpage><pub-id pub-id-type="pmid">12531774</pub-id></citation></ref><ref id="pone.0004778-Oral1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oral</surname><given-names>HB</given-names></name><name><surname>Budak</surname><given-names>F</given-names></name><name><surname>Uzaslan</surname><given-names>EK</given-names></name><name><surname>Basturk</surname><given-names>B</given-names></name><name><surname>Bekar</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>Interleukin-10 (IL-10) gene polymorphism as a potential host susceptibility factor in tuberculosis.</article-title><source>Cytokine</source><volume>35</volume><fpage>143</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">16962335</pub-id></citation></ref><ref id="pone.0004778-Sallakci1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sallakci</surname><given-names>N</given-names></name><name><surname>Coskun</surname><given-names>M</given-names></name><name><surname>Berber</surname><given-names>Z</given-names></name><name><surname>G&#x000fc;rkan</surname><given-names>F</given-names></name><name><surname>Kocamaz</surname><given-names>H</given-names></name><etal/></person-group><year>2007</year><article-title>Interferon-gamma gene&#x0002b;874T-A polymorphism is associated with tuberculosis and gamma interferon response.</article-title><source>Tuberculosis</source><volume>87</volume><fpage>225</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">17276141</pub-id></citation></ref><ref id="pone.0004778-Etokebe1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Etokebe</surname><given-names>G</given-names></name><name><surname>Bulat-Kardum</surname><given-names>L</given-names></name><name><surname>Johansen</surname><given-names>M</given-names></name><name><surname>Knezevic</surname><given-names>J</given-names></name><name><surname>Balen</surname><given-names>S</given-names></name><etal/></person-group><year>2006</year><article-title>Interferon-gamma gene (T874A and G2109A) polymorphisms are associated with microscopy-positive tuberculosis.</article-title><source>Scand J Immunol</source><volume>63</volume><fpage>136</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">16476013</pub-id></citation></ref><ref id="pone.0004778-Moran1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Reich</surname><given-names>RA</given-names></name><name><surname>Graviss</surname><given-names>EA</given-names></name></person-group><year>2007</year><article-title>No association between the &#x0002b;874T/A single nucleotide polymorphism in the IFN-g gene and susceptibility to TB.</article-title><source>Int J Tuberc Lung Dis</source><volume>11</volume><fpage>113</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">17217140</pub-id></citation></ref><ref id="pone.0004778-Vidyarani1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vidyarani</surname><given-names>M</given-names></name><name><surname>Selvaraj</surname><given-names>P</given-names></name><name><surname>Adnand</surname><given-names>AP</given-names></name><name><surname>Jawahar</surname><given-names>MS</given-names></name><name><surname>Adhilakshmi</surname><given-names>AR</given-names></name><etal/></person-group><year>2006</year><article-title>Interferon gamma (IFN&#x003b3;) &#x00026; interleukin-4 (IL-4) gene variants &#x00026; cytokine levels of pulmonary tuberculosis.</article-title><source>Indian J Med Res</source><volume>124</volume><fpage>403</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">17159260</pub-id></citation></ref><ref id="pone.0004778-Henao1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henao</surname><given-names>MI</given-names></name><name><surname>Montes</surname><given-names>C</given-names></name><name><surname>Paris</surname><given-names>SC</given-names></name><name><surname>Garcia</surname><given-names>LF</given-names></name></person-group><year>2006</year><article-title>Cytokine gene polymorphisms in Colombian patients with different clinical presentations of tuberculosis.</article-title><source>Tuberculosis</source><volume>86</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">15925543</pub-id></citation></ref><ref id="pone.0004778-Cooke1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooke</surname><given-names>GS</given-names></name><name><surname>Campbell</surname><given-names>SJ</given-names></name><name><surname>Sillah</surname><given-names>J</given-names></name><name><surname>Gustafson</surname><given-names>P</given-names></name><name><surname>Bah</surname><given-names>B</given-names></name><etal/></person-group><year>2006</year><article-title>Polymorphism within the Interferon-g/ Receptor Complex is associated with Pulmonary Tuberculosis.</article-title><source>Am J Respir Crit Care Med</source><volume>174</volume><fpage>339</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">16690980</pub-id></citation></ref><ref id="pone.0004778-FloresVillanueva1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flores-Villanueva</surname><given-names>PO</given-names></name><name><surname>Ruiz-Morales</surname><given-names>JA</given-names></name><name><surname>Song</surname><given-names>CH</given-names></name><name><surname>Flores</surname><given-names>LM</given-names></name><name><surname>Jo</surname><given-names>EK</given-names></name><etal/></person-group><year>2005</year><article-title>A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with increased susceptibility to pulmonary tuberculosis.</article-title><source>J Exp Med</source><volume>202</volume><fpage>1649</fpage><lpage>1658</lpage><pub-id pub-id-type="pmid">16352737</pub-id></citation></ref><ref id="pone.0004778-Sahiratmadja1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sahiratmadja</surname><given-names>E</given-names></name><name><surname>Alisjahbana</surname><given-names>B</given-names></name><name><surname>de Boer</surname><given-names>T</given-names></name><name><surname>Adnan</surname><given-names>I</given-names></name><name><surname>Maya</surname><given-names>A</given-names></name><etal/></person-group><year>2007</year><article-title>Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment.</article-title><source>Infect Immun</source><volume>75</volume><fpage>820</fpage><lpage>829</lpage><pub-id pub-id-type="pmid">17145950</pub-id></citation></ref><ref id="pone.0004778-Turner1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>DM</given-names></name><name><surname>Williams</surname><given-names>DM</given-names></name><name><surname>Sankaran</surname><given-names>D</given-names></name><name><surname>Lazarus</surname><given-names>M</given-names></name><name><surname>Sinnott</surname><given-names>PJ</given-names></name><etal/></person-group><year>1997</year><article-title>An Investigation of polymorphism in the interleukin-10 gene promoter.</article-title><source>Eur J Immunogen</source><volume>24</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9043871</pub-id></citation></ref><ref id="pone.0004778-Hussain1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>R</given-names></name><name><surname>Kaleem</surname><given-names>A</given-names></name><name><surname>Shahid</surname><given-names>F</given-names></name><name><surname>Dojki</surname><given-names>M</given-names></name><name><surname>Jamil</surname><given-names>B</given-names></name><etal/></person-group><year>2002</year><article-title>Cytokine profiles using whole blood assays can discriminate between tuberculosis patients and healthy endemic controls in BCG-vaccinated population.</article-title><source>J Immunol Meth</source><volume>264</volume><fpage>95</fpage><lpage>108</lpage></citation></ref><ref id="pone.0004778-Bellamy1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bellamy</surname><given-names>R</given-names></name></person-group><year>2003</year><article-title>Susceptibility to mycobacterial infections: the importance of host genetics.</article-title><source>Genes Immun</source><volume>4</volume><fpage>4</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">12595896</pub-id></citation></ref><ref id="pone.0004778-Shin1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>HD</given-names></name><name><surname>Park</surname><given-names>BL</given-names></name><name><surname>Kim</surname><given-names>LH</given-names></name><name><surname>Cheong</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>IH</given-names></name><etal/></person-group><year>2005</year><article-title>Common interleukin 10 polymorphism associated with deceased risk of tuberculosis.</article-title><source>Exp Mol Med</source><volume>37</volume><fpage>128</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">15886526</pub-id></citation></ref><ref id="pone.0004778-Scola1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scola</surname><given-names>L</given-names></name><name><surname>Crivello</surname><given-names>A</given-names></name><name><surname>Marino</surname><given-names>V</given-names></name><name><surname>Gioia</surname><given-names>V</given-names></name><name><surname>Serauto</surname><given-names>A</given-names></name><etal/></person-group><year>2003</year><article-title>IL-10 and TNF-alpha polymorphisms in a sample of Sicilian patients affected by tuberculosis: implication for ageing and life span expectancy.</article-title><source>Mech Ageing Dev</source><volume>124</volume><fpage>569</fpage><lpage>572</lpage><pub-id pub-id-type="pmid">12714269</pub-id></citation></ref><ref id="pone.0004778-Delgado1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delgado</surname><given-names>JC</given-names></name><name><surname>Baena</surname><given-names>A</given-names></name><name><surname>Thim</surname><given-names>S</given-names></name><name><surname>Goldfeld</surname><given-names>AE</given-names></name></person-group><year>2002</year><article-title>Ethnic-Specific genetic associations with pulmonary tuberculosis.</article-title><source>J Infect Dis</source><volume>186</volume><fpage>1463</fpage><lpage>1468</lpage><pub-id pub-id-type="pmid">12404162</pub-id></citation></ref><ref id="pone.0004778-Hussain2"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>R</given-names></name><name><surname>Talat</surname><given-names>N</given-names></name><name><surname>Shahid</surname><given-names>F</given-names></name><name><surname>Dawood</surname><given-names>G</given-names></name></person-group><year>2007</year><article-title>Longitudinal tracking of cytokines after acute exposure to Tuberculosis: Association of Distinct Cytokine patterns with protection and disease development.</article-title><source>Clin Vaccine Immunol</source><volume>14</volume><fpage>1578</fpage><lpage>1586</lpage><pub-id pub-id-type="pmid">17928427</pub-id></citation></ref><ref id="pone.0004778-Maher1"><label>40</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Maher</surname><given-names>D</given-names></name><name><surname>Chaulet</surname><given-names>P</given-names></name><name><surname>Spinaci</surname><given-names>S</given-names></name><name><surname>Harries</surname><given-names>A</given-names></name></person-group><year>1997</year><source>Treatment of Tuberculosis - Guidelines for National Programmes</source><publisher-name>World Health Organization</publisher-name><fpage>1</fpage><lpage>78</lpage></citation></ref><ref id="pone.0004778-Perrey1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perrey</surname><given-names>C</given-names></name><name><surname>Pravica</surname><given-names>V</given-names></name><name><surname>Sinnott</surname><given-names>PJ</given-names></name><name><surname>Hutchinson</surname><given-names>IV</given-names></name></person-group><year>1998</year><article-title>Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumor necrosis factor-alpha genes: a technical report.</article-title><source>Transpl Immunol</source><volume>6</volume><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">9848226</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was funded by The Grant No PCST/NCB-AC3/2003 and by the Higher Education Commission of Pakistan Grant No 20-796/ R and D/07 Government of Pakistan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 